

Adam L Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6482654/publications.pdf>

Version: 2024-02-01

37
papers

3,057
citations

394421

19
h-index

345221

36
g-index

40
all docs

40
docs citations

40
times ranked

6069
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. <i>Nature Medicine</i> , 2019, 25, 477-486.	30.7	932
2	Glioma Subclassifications and Their Clinical Significance. <i>Neurotherapeutics</i> , 2017, 14, 284-297.	4.4	471
3	IDH1 and IDH2 Mutations in Gliomas. <i>Current Neurology and Neuroscience Reports</i> , 2013, 13, 345.	4.2	469
4	Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 5425-5430.	7.1	190
5	Glioma Biology and Molecular Markers. <i>Cancer Treatment and Research</i> , 2015, 163, 15-30.	0.5	161
6	Combating subclonal evolution of resistant cancer phenotypes. <i>Nature Communications</i> , 2017, 8, 1231.	12.8	124
7	Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future. <i>Current Treatment Options in Oncology</i> , 2016, 17, 42.	3.0	95
8	New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 19.	4.2	87
9	DNA copy number analysis of Grade II–III and Grade IV gliomas reveals differences in molecular ontogeny including chromothripsis associated with IDH mutation status. <i>Acta Neuropathologica Communications</i> , 2015, 3, 34.	5.2	64
10	A pharmacogenomic method for individualized prediction of drug sensitivity. <i>Molecular Systems Biology</i> , 2011, 7, 513.	7.2	43
11	Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas. <i>Neurosurgical Focus</i> , 2015, 38, E2.	2.3	42
12	Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database. <i>Journal of Neurosurgery</i> , 2018, 128, 1133-1138.	1.6	37
13	Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers. <i>BMC Medical Genomics</i> , 2013, 6, 35.	1.5	36
14	Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes. <i>Journal of Molecular Medicine</i> , 2017, 95, 1167-1178.	3.9	34
15	Serial single-cell genomics reveals convergent subclonal evolution of resistance as patients with early-stage breast cancer progress on endocrine plus CDK4/6 therapy. <i>Nature Cancer</i> , 2021, 2, 658-671.	13.2	34
16	IGFBP2 expression predicts IDH-mutant glioma patient survival. <i>Oncotarget</i> , 2017, 8, 191-202.	1.8	30
17	Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer. <i>Nature Communications</i> , 2021, 12, 3039.	12.8	24
18	A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. <i>Oncotarget</i> , 2017, 8, 52413-52419.	1.8	21

#	ARTICLE	IF	CITATIONS
19	The relationship between monoclonal gammopathy of undetermined significance and venous thromboembolic disease. <i>Thrombosis Research</i> , 2010, 125, 216-219.	1.7	20
20	Development of the Electronic Social Network Assessment Program Using the Center for eHealth and Wellbeing Research Roadmap. <i>JMIR Human Factors</i> , 2017, 4, e23.	2.0	18
21	Challenges of targeting <i>BRAF</i> V600E mutations in adult primary brain tumor patients: a report of two cases. <i>CNS Oncology</i> , 2019, 8, CNS48.	3.0	17
22	Genomic classification of the RAS network identifies a personalized treatment strategy for lung cancer. <i>Molecular Oncology</i> , 2014, 8, 1339-1354.	4.6	14
23	Integrative analyses reveal signaling pathways underlying familial breast cancer susceptibility. <i>Molecular Systems Biology</i> , 2016, 12, 860.	7.2	14
24	Gene-expression patterns in peripheral blood classify familial breast cancer susceptibility. <i>BMC Medical Genomics</i> , 2015, 8, 72.	1.5	13
25	Leptomeningeal dissemination of a low-grade lumbar paraganglioma: case report. <i>Journal of Neurosurgery: Spine</i> , 2017, 26, 501-506.	1.7	10
26	POWERPIINC (PreOperative Window of Endocrine Therapy Provides Information to Increase) Tamoxifen. <i>Breast</i> , 2017, 31, 219-223.	2.2	10
27	Caregiver burden by treatment and clinical characteristics of patients with glioblastoma. <i>Supportive Care in Cancer</i> , 2022, 30, 1365-1375.	2.2	8
28	A Phase I Study of Neoadjuvant Chemotherapy With Nab-Paclitaxel, Doxorubicin, and Cyclophosphamide in Patients With Stage II to III Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 503-509.	2.4	7
29	Repeat radiation with bevacizumab and minocycline in bevacizumab-refractory high grade gliomas: a prospective phase 1 trial. <i>Journal of Neuro-Oncology</i> , 2020, 148, 577-585.	2.9	7
30	Opportunities for improving cancer treatment using systems biology. <i>Current Opinion in Systems Biology</i> , 2019, 17, 41-50.	2.6	5
31	Novel temporal and spatial patterns of metastatic colonization from breast cancer rapid-autopsy tumor biopsies. <i>Genome Medicine</i> , 2021, 13, 170.	8.2	5
32	Association between the 21-gene recurrence score and isolated locoregional recurrence in stage I-II, hormone receptor-positive breast cancer. <i>Radiation Oncology</i> , 2020, 15, 198.	2.7	4
33	Risk Reduction Strategies for Ductal Carcinoma In Situ. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 1211-1217.	4.9	2
34	The contribution of the rs55705857 G allele to familial cancer risk as estimated in the Utah population database. <i>BMC Cancer</i> , 2019, 19, 190.	2.6	2
35	ACTR-19. A MULTICENTER PILOT PHASE II STUDY OF CONTINUING TMZ WITH THE ADDITION OF DISULFIRAM AND COPPER FOR REFRACTORY GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi15-vi15.	1.2	0
36	HOUT-01. A RETROSPECTIVE ANALYSIS OF OUTCOMES WITH TEMOZOLOMIDE AS INITIAL TREATMENT OF GRADE 2 OLIGODENDROGLIOMA. <i>Neuro-Oncology</i> , 2018, 20, vi113-vi113.	1.2	0

#	ARTICLE	IF	CITATIONS
37	PATH-54. UTILITY OF NEXT GENERATION SEQUENCING IN ADULT PRIMARY BRAIN TUMORS: IMPACT ON DIAGNOSIS AND PERSONALIZED THERAPY. <i>Neuro-Oncology</i> , 2018, 20, vi170-vi170.	1.2	0